[Clinical use of pterofen as a diuretic agent in circulatory insufficiency].
Clinical and laboratory observations were conducted using a new Soviet-made drug Pterophene as a diuretic in 30 patients with circulatory insufficiency. Stage IIB and III. Pterophene was found to produce a distinct natriuretuc and diuretic effect. With its daily intake, the effect has a prompt onset, it increases by the 3rd-4th day of therapy, persists for a long period, slightly decreasing in its potency by the 7th-10th day of its continuous administration. A valuable property of Pterophene is its potassium-retaining effect. The drug is well tolerated by the patients, and it can be combined with other diuretics. Pherophene potentiates the diuretic and natriuretic effect of Hypothiaside, Furosemide and Nuvorite, and decreases potassium excretion that was enhanced by these drugs.
D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003327:Coronary Disease / Q000188:drug therapy; D004231:Diuresis / Q000187:drug effects; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D011660:Pulmonary Heart Disease / Q000188:drug therapy; D012214:Rheumatic Heart Disease / Q000188:drug therapy; D014223:Triamterene / Q000627:therapeutic use*
D014223:Triamterene
Klinicheskoe primenenie pterofena kak mochegonnogo sredstva pri nedostatochnosti krovoobrashcheniia